DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.55
+0.40 (6.50%)
At close: Jun 26, 2026, 4:00 PM EDT
6.55
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
DiaMedica Therapeutics Employees
DiaMedica Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 7 or 25.00% compared to the previous year.
Employees
35
Change (1Y)
7
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,002,886
Market Cap
352.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Verastem | 102 |
| OmniAb | 89 |
| Upstream Bio | 75 |
| Lexeo Therapeutics | 59 |
| Atea Pharmaceuticals | 55 |
| X4 Pharmaceuticals | 45 |
DMAC News
- 4 days ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly
- 5 days ago - DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
- 12 days ago - DiaMedica Therapeutics receives written response from FDA on DM199 - TheFly
- 12 days ago - DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
- 26 days ago - DiaMedica Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - Business Wire
- 5 weeks ago - DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial - TheFly
- 5 weeks ago - DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire